The beneficial effects of corticosteroid therapy in the treatment of rheumatic diseases may be offset by the occurrence of corticosteroid-related osteoporosis. This problem may be overcome by using low-dose corticosteroids; however, the dose of corticosteroids that is both efficacious and skeletal sparing is uncertain. Therefore, the aim of this study was to determine whether low-dose prednisolone treatment results in bone loss and modifies bone turnover. Nineteen patients (12 female, seven male) suffering from polymyalgia rheumatica received 10 mg or less daily, given in reducing dosage, with a range of 2.5-10 mg and an average of 6.0 ± 0.2 mg daily (±...). Prior to the commencement of therapy and at regular intervals during treatment, bone mineral density (BMD) using dual X-ray absorptiometry and circulating biochemical and hormonal determinants of bone turnover were measured. The patients were followed for 14.4 ± 1.6 months (range 6-27). They were compared to 19 age-matched controls. Despite a mean exposure dose of 6 mg/day and disease remission, BMD decreased in the patients at the lumbar spine (2.6 ± 0.8%, P < 0.01), femoral neck (2.9 ± 1.5%, P = 0.06), Ward's triangle (5.5 ± 2.9%, P = 0.06) and the trochanter (4.3 ± 1.9%, P < 0.05). Total body bone mass decreased by 50 ± 19 g in the first 6 months (P < 0.02), and by 39 ± 30 g in the remaining 8 months of follow-up [not significant (NS)]. In the first 6 months, BMD decreased at the lumbar spine (1.7 ± 0.9%, P = 0.06). From 6 months to the end of follow-up, BMD decreased by 8.5 ± 3.5% at Ward's triangle (P < 0.05) and by 4.8 ± 2.5% at the femoral neck (P = 0.08). The fall in BMD correlated with the cumulative prednisolone dose at trabecular-rich regions (trunk r = −0.72, P < 0.001; ribs r = −0.53, P < 0.05). Bone resorption, assessed by urinary cross-laps, was 54.7% higher than controls before treatment was started (P < 0.05) and decreased by 23.5 ± 7.1% in the first month of treatment when the mean prednisolone dose was 9.1 mg/day, range 5-10 (P < 0.0001). Serum osteocalcin was not suppressed by disease before treatment, decreased by 27.4 ± 5.1% during the first month of treatment (P < 0.001), remained suppressed while the daily dose of prednisolone was >5 mg/day, but returned to baseline below this dose. Serum parathyroid hormone was 19.3% lower in the patients than controls at baseline (NS ), and increased by 46.1% (P < 0.05) but was no higher than controls at any time. Muscle strength increased by 20-60% (P < 0.05 to < 0.01). Prophylaxis should be considered in patients receiving Á5 mg/day prednisolone daily as bone loss is 2-to 3-fold expected rates. Earlier trabecular bone loss may predispose to spine and rib fracture; later cortical bone loss may predispose to hip fractures. Doses of prednisolone of < 5 mg daily may be skeletal sparing, but may not be efficacious.
C therapy has an important role in the to treatment and are likely to receive lower doses of management of many chronic inflammatory and noncorticosteroids [7] [8] [9] [10] . inflammatory illnesses. However, the benefits derived Exposure to corticosteroids before the onset of a from the use of corticosteroids may be offset by the clinical study is common and may result in an underoccurrence of corticosteroid-related osteoporosis. In estimate of the effects of corticosteroids, particularly principle, this problem may be overcome by using lowif an accelerated phase of bone loss had occurred dose corticosteroids. In practice, the dose of corticoduring the initial months of therapy [2, 5, 10, 12] . In steroids that is both efficacious and skeletal sparing is addition, the retrospective estimation of exposure uncertain. dosage in cross-sectional studies is likely to be unreliThe lack of credible information concerning the able as dosage schedules are rarely recorded meticuminimum dose of corticosteroids that improves the lously and compliance cannot be verified [1, 3, 7 , 10, clinical and biochemical features of disease without 13, 14] . Moreover, study participants differ by age causing bone loss is due to the many co-existing and [1, 2, 5, 8, 11] , gender [1, 2, 4, 5, 7, 8, 11, 13] , years independent factors that influence bone density [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] .
since menopause [1-3, 5, 6, 8, 9, 12, 13] and the type For example, the illness to be treated may result in of illness being treated [1, 2, 4, 5, 8, 11] ; all important bone loss and its severity may influence the dose of independent determinants of bone density. These faccorticosteroids chosen [1] [2] [3] [4] [5] [6] [7] [8] . The purported safety of tors may either account for the failure to detect an lower doses of corticosteroids may be the result of this association between dose and bone density, or may sampling bias; patients with less severe illness and be responsible for any reported association. Many greater mobility may have higher bone density prior patients receive treatment (other than corticosteroids) that may influence bone density directly or through the drug's effect on the underlying illness [1, 6, 12, 13 , methods used to measure bone density is 2-3%, similar and biochemical improvement occurred. Treatment regimens were [daily dose (number of patients to the expected change with treatment [1, 4, 5, 8-11, treated)]: 10 mg (13 for 1 and one for 2 months) ; 14] . Cortical bone has a lower turnover than trabecular 8.5 mg (one for 1 month); 8 mg (one for 2 months); bone [17] . Thus, measurements confined to predomin-7.5 mg (four for 1, eight for 2, two for 3 and one for antly cortical regions may be less sensitive to cortico-4 months); 5 mg (six for 1, three for 2, one for 3, three steroids than those in trabecular-rich regions [3] . In for 4 and one for 6 months); 4 mg (one for 2 months); addition, small numbers of participants and brief 3.5 mg (one for 2 months); 3 mg (two for 1 month); follow-up may result in null observations [1, 4, 7, 12] .
2.5 mg (seven for 1, two for 2 and one for 6 months). These problems in study design, execution and interThe patients were followed for a mean of 14.4 months, pretation are also partly responsible for there being ranging from 6 to 27 months (four for 6, one for 9, several unanswered questions concerning the pathogenseven for 12, one for 15, three for 21 and three for 27 esis of corticosteroid-related bone loss. Reduced bone months). formation has been consistently shown to contribute
The patients were compared with controls (15 to bone loss [18] [19] [20] [21] [22] [23] . Whether increased bone resorpfemales, four males) recruited from a normal agetion occurs is less clear. The hormonal changes held matched population who were followed for to be responsible for reduced bone formation or 13.1 ± 1.3 yr. It was not possible to randomize the two increased bone resorption may be the result of disease groups because corticosteroids cannot be given to activity before and during treatment, not the corticohealthy subjects or withheld from patients. Eight steroids [16 ] . Although secondary hyperparathyroidpatients were excluded because of prior corticosteroid ism is often cited as a cause of bone loss, reduced, therapy and three preferred not to participate. No normal or elevated circulating parathyroid hormone patients received >10 mg/day during the study, so no (PTH ) levels have been reported [24] [25] [26] [27] [28] [29] [30] . Rather than patients were excluded on this basis. One male control causing bone loss, PTH may be suppressed as a conwas excluded when found to be hypogonadal. sequence of bone loss secondary to illness and immobilMeasurements were made before treatment, monthly ity. Changes in gonadal and adrenal steroids, growth for 3 months and then 3 monthly. hormone and insulin-like growth factor 1 (IGF-1)
Total body and regional bone density were measured have been implicated in the pathogenesis of reduced by dual X-ray absorptiometry (g/cm2; Lunar Corp., bone formation [31] [32] [33] [34] .
Madison, WI, USA) [35] . The coefficients of variation To overcome some of these difficulties, and to were determined in our own department, on our own address several of these questions, we conducted a machines, and ranged from 1.5 to 2.4%. Isokinetic controlled prospective study in patients with newly muscle strength, generated during flexion and extension diagnosed polymyalgia rheumatica who received 10 mg of the knee and hip at 60°/s, and during shoulder or less of prednisolone daily and had no prior exposure internal and external rotation at 30°/s, was measured to corticosteroids. The patients received no other drugs in the patients using dynamometry (Merac, Universal, and had no other illnesses known to affect bone. We Cedar Rapids, IA, USA). The coefficient of variation asked the following questions. (i) Does corticosteroid for the movements ranged from 2.6 to 5.6% ( lower therapy of 10 mg per day or less result in bone loss? limb) and from 10.9 to 13.7% (upper limb). (ii) Is there a dose-response relationship? (iii) Is bone Morning blood and urine samples were collected in loss accelerated in the early stages of treatment? Does all subjects, frozen and stored at −20°C until the end it diminish with time? (iv) What is the pathogenesis of of the study. Serum osteocalcin was measured with a bone loss? human specific immunoradiometric assay (ng/ml; ELISA-OSTEO@, Cis BiointernationalA, France) which recognizes a large N-terminal mid-fragment and PATIENTS AND METHODS the intact molecule [36 ] . Serum bone alkaline phosAll consecutive patients with polymyalgia rheumphatase was measured with an immunoradiometric atica at the Alfred Hospital, Melbourne, between 1992 assay using two monoclonal antibodies directed against and 1995, were considered for participation in the the human bone isoenzyme (Ostase@, Hybritech IncA, study. We studied 19 patients (12 post-menopausal USA) [37] . Serum collagen propeptide of type 1 women, seven men) aged 71.8 ± 1.6 yr with polymyalcollagen (P1CP) was measured with a two-site gia rheumatica. Diagnostic criteria included: (1) symenzyme-linked immunoassay (ELISA) which uses a metrical upper and lower limb girdle myalgia for 6 polyclonal and a monoclonal antibody raised against weeks or more; (2) erythrocyte sedimentation rate human procollagen 1 carboxypeptide purified from ( ESR) >50 mm/h; (3) absence of obvious polyskin fibroblast culture (Procollagen-C@, Metra arthritis, polytendonitis or polymyositis; (4) no clinical BiosystemsA, USA) [38] . Bone resorption was assessed evidence of giant cell arteritis; (5) negative rheumatoid by measuring urinary type 1 C-telopeptide breakdown factor, antinuclear antibody and normal creatinine products with an ELISA (CTX, cross laps@, phosphokinase levels.
Osteometer A/SA, Denmark) based on an immobilized The patients were treated with 10 mg/day of prednisynthetic peptide with an amino acid sequence specific solone or less, which averaged 6.0 ± 0.2 mg/day during for a part of the C-telopeptide of the alpha 1 chain of type 1 collagen [39] . the observation period. The dose was tapered as clinical 25.5 ± 3.1 26.4 ± 2.2 −2.9 ± 2.6 1.5 ± 2.5 Alkaline phosphatase (ng/ml ) 9.9 ± 1.0 11.1 ± 1.2 3.5 ± 0.7 ‡ ‡ 2.3 ± 1.0 P1CP (ng/ml ) 95.0 ± 6.2 88.6 ± 6.1 7.3 ± 6.6 9.5 ± 4.8 Androstenedione (ng/ml ) 3.5 ± 0.4 2.8 ± 0.4
72.6 ± 7.0 85.1 ± 6.4 11.5 ± 5.7 ‡ −0.8 ± 7.4 Growth hormone (ng/ml ) 3.2 ± 0.5 3.3 ± 0.9 −1.0 ± 0.6 −1.0 ± 1.1
Data expressed as mean ± ... CTX, cross-laps; P1CP, procollagen 1 carboxypeptide; IGF-1, insulin-like growth factor 1; DHEA-S, dehydroepiandrosterone sulphate. *P < 0.06; **P < 0.05 compared to controls. †P ∏ 0.09; † †P < 0.05; ‡P < 0.01; ‡ ‡P < 0.001 compared to zero.
Serum intact PTH was measured by an immunoradio-RESULTS metric assay (pg/ml; Nichols Institute Diagnostics, San
The patients received a mean prednisolone dose of Luan Capistrano, CA, USA). Serum calcium and 6.0 ± 0.23 mg/day (range 2.5-10) and a cumulative creatinine (mmol/l ) were measured photometrically dose of 2356 ± 244 mg (range 1065-4765). Remission using the Hitachi autoanalyser. A radioimmunoassay was characterized by resolution of muscle pain and was used to measure growth hormone (GH; ng/ml; weakness, and a fall in ESR from 58.9 ± 4.5 mm/h at Growth Hormone Spectra Kit, Orion Diagnostica, baseline to 15.3 ± 3.8, 14.5 ± 3.1 and 11.6 ± 2.2 mm/h Finland), IGF-1 (ng/ml; using anti-human IGF-1 polyat 3, 6 and 12 months, respectively (all P < 0.0001 clonal antibodies raised in rabbits), serum dehydroepicompared to baseline). androsterone sulphate (DHEA-S; ng/ml; Direct RIA As shown in Table I , the patients were~5 yr older Kit, Biotecx, Houston, TX, USA) and androstenedione than the controls due to exclusion of the hypogonadal (ng/ml; Direct Androstenedione Kit, Diagnostics male control. There was no significant age difference Biochem Canada Inc., Ontario, Canada). Testosterone, between the female patients and controls (70.0 ± 1.9 sex steroid binding globulin (SHBG), luteinizing horand 66.0 ± 1.4 yr, respectively). There were no differmone (LH ) and follicle-stimulating hormone (FSH ) ences in baseline bone density in the patients and were measured in the men. Testosterone was measured controls, before or after adjusting for age. The columns using a competitive chemiluminescent immunoassay 'Changes' show the mean of the paired difference (Ciba Corning ASC5180 machine, Australian (baseline minus final ) in bone density in each subject. Diagnostics). SHBG was measured using an immunoBone density decreased at the each site in the patients, radiometric assay (nmol/l; SHBG Spectra Kit, Orion not controls. The decrease in the patients was Diagnostica, Finland). FSH and LH were meas-2.6 ± 0.8% at the lumbar spine (P < 0.01), 2.9 ± 1.5% ured using a two-site chemiluminometric immunoat the femoral neck (P = 0.06), 5.5 ± 2.9% at Ward's assay (mIU/l; Ciba Corning ACS5180 machine, triangle (P = 0.06) and 4.3 ± 1.9% at the trochanter Australian Diagnostics). Coefficients of variation for (P < 0.05). The change was greater in the patients the assays were 5-10%.
than the controls at the lumbar spine (−2.6 ± 0.8% vs Analyses were performed using Statview II (Abacus −0.2 ± 0.9%, P < 0.06) and trochanter (−4.3 ± 1.9% Concepts Inc., Berkeley, CA, USA). Paired t-tests were vs 0.8 ± 1.4%, P < 0.05). used to compare the pre-and post-treatment results in Total body bone mineral content decreased by the patients and controls. Differences between the two 50 ± 19 g (2.1 ± 0.7%; P < 0.02) in the first 6 months groups were analysed using ANOVA. Adjustments for and by 39 ± 30 g [1.9 ± 1.4%; not significant (NS)] age were made using ANCOVA. The relationship from 6 to 14 months. The change in bone density was between bone density and the cumulative dose of site specific and varied according to the duration of prednisolone was examined using simple regression.
therapy. Table II shows the changes expressed in absolute terms. Figure 1 shows the changes expressed in The data were expressed as mean ± ... F. 1.-Percentage changes in bone density at the axial skeleton ( left panel ) and the proximal femur (right panel ) in patients during the first 6 months and from 6 months to the end of prednisolone treatment (mean ± ...). *P < 0.09; **P < 0.05 compared to previous measurement.
percentage terms. Bone density at the spine decreased by 1.7 ± 0.9% (P = 0.06) in the first 6 months (expressed as a percentage of the baseline value) and by 1.0 ± 0.6% from 6 to 14 months (expressed as a percentage of the 6 month value) (NS). Bone density decreased at the trochanter by 2.5 ± 1.9% in the first 6 months (P = 0.1) and by 1.7 ± 6.5% from 6 months to the final observation (NS). There was no significant change in the first 6 months at the femoral neck and Ward's triangle (0.9 ± 2.4 and 0.1 ± 3.4%, respectively). From 6 to 14 months of follow-up, bone density decreased by 8.5 ± 3.5% (P < 0.05) at Ward's triangle and by 4.8 ± 2.5% at the femoral neck (P = 0.08). The total decrease in bone density correlated negatively with the cumulative prednisolone dose at the trunk (r = −0.72, P < 0.001), the ribs (r = −0.53, P < 0.05) and the lumbar spine (r = −0.3, P = 0.16) ( Fig. 2) .
F. 3.-The absolute changes in urinary cross-laps (CTX ), osteoAs shown in Table I , at baseline, before prednisolone calcin and skeletal alkaline phosphatase in the patients during was started, bone resorption, as assessed by urinary prednisolone treatment (mean ± ...). *P ∏ 0.09; **P < 0.05; †P < 0.01; ‡P < 0.001 compared to baseline.
CTX, was 54.7% higher in the patients (P < 0.01). ( Urinary CTX was also higher in the female patients than female controls: 263 ± 40 and 146 ± 30 ml/mmol, respectively, P < 0.05.) As shown in Fig. 3, urinary period (mean of 14 months), the mean urinary CTX was 167 ± 20 ml/mmol, below the baseline value of CTX decreased and had a trend towards higher values in the latter months of treatment among the small 224 ± 28 ml/mmol (P < 0.05), and no longer greater than in controls (205 ± 42 ml/mmol ). There were no number of patients followed at time points beyond 15 months. At the end of the 6-27 month observation changes in the controls.
F. 4.-Absolute changes in parathyroid hormone (pg/ml ) and serum calcium (mmol/l ) in patients ($) and controls (#) (mean ± ...). **P < 0.05 compared to baseline.
As shown in Table I , at baseline, before prednisolone was started, bone formation, as assessed by serum osteocalcin, was not suppressed. As shown in Fig. 3 , at the end of the first month of therapy, serum osteocalcin decreased by 27.4 ± 5.1% (P < 0.0001). Osteocalcin tended to increase during the later stages of treatment. At the end of the follow-up period of 14 months (ranging from 6 to 27), when the mean dose of prednisolone was 3.6 mg/day (range 2.5-7.5), the mean serum osteocalcin was 23.0 ± 2.6 ng/ml, no different to controls (29.0 ± 3.5 ng/ml ) or to the pretreatment value (25.5 ± 3.1 ng/ml ). The osteocalcin levels did not change in the controls.
Skeletal alkaline phosphatase increased by 11.8 ± 1.6% (P < 0.05) in the first month (Fig. 3 ). There were no changes in the controls. The P1CP levels did not change in the patients or the controls (data not shown). Figure 5 shows that serum PTH was 19.3% lower in the patients than controls at baseline (3.9 ± 0.6 vs 4.8 ± 0.9 pg/ml, respectively) and increased by 46.1 ± 12.8% in the patients (P < 0.05), but did not was serum PTH higher than in controls. Serum calcium *P ∏ 0.09; **P < 0.05; †P < 0.01; ‡P < 0.001; † †P < 0.0001 comdid not differ between the groups at baseline (patients pared to baseline.
2.3 ± 0.04 vs controls 2.2 ± 0.05 mmol/l ) and did not change in either group (patients −1.3 ± 2.9% vs controls DISCUSSION 0.9 ± 3.1%).
This study was designed to address the efficacy and Androstenedione, DHEA-S, IGF-1 and GH did not safety of 'low'-dose corticosteroids in the absence of differ relative to controls at baseline (Table I) . As shown several independent factors that may influence bone in Fig. 5 , in the first month of treatment, androstenedensity. Patients were excluded if they had had expodione decreased by 55.6 ± 5.5% (P < 0.0001), DHEA-S sure to corticosteroids before the study or exposure to decreased by 14.5 ± 5.2% (P < 0.01) and IGF-1 >10 mg/day at any time. The patients were ambulant, increased by 67.3 ± 21.5% (P < 0.0001). During the 14 they received no other bone-modulating treatment months, there were no detectable changes in patients or or had no other illnesses known to affect bone. The controls in GH (measured in women and men), testosterdose and duration of treatment were documented one, LH, FSH or SHBG (measured in the men) (data prospectively. not shown). There were no changes in the controls.
We report the following. (i) Treatment with Muscle strength increased in all but one patient. The an average of 6 mg/day produced remission with mean increases were 32.8 ± 8.0% (shoulder internal improved mobility and muscle strength. Bone loss rotation, P < 0.01), 61.5 ± 12.7% (shoulder external occurred at this 'low' mean daily dose.
(ii) The pattern rotation, P < 0.001), 31.2 ± 19.2% (knee extension, of bone loss was site specific; occurring at the spine, a P < 0.07), 22.9 ± 8.3% (hip flexion, P < 0.05) and region containing substantial amounts of trabecular 46.2 ± 11.5% (hip extension, P < 0.01). Seven of the bone, in the first 6 months, and becoming measurable 17 patients were unable to perform one or more of the at the proximal femur, a predominantly cortical site, movements at baseline. All were able to perform in the latter months of the study. (iii) Bone loss is the movements after 4 weeks treatment, except one, likely to be due to reduced bone formation. Serum who was unable to perform the shoulder movements for the duration of the study.
osteocalcin was reduced when prednisolone doses were Á5 mg daily. Increased bone resorption was a conbone was measured. Cortical bone loss may have sequence of the illness, not its treatment, as urinary occurred during the later stages of therapy. Similarly, CTX was elevated before treatment and decreased Sambrook et al. [5] concluded that bone loss with during treatment. (iv) There was no evidence for corticosteroids is most rapid soon after starting treatsecondary hyperparathyroidism.
ment. This conclusion was not based on comparing Skeletal sparing has been reported using 5-10 mg earlier and later rates of bone loss in the same patients. prednisolone daily. These null observations may have More rapid bone loss was reported in 17 patients been due to: (i) the imprecision of dual photon (mean age 54.7 yr) treated for the first time with absorptiometry and neutron activation compared with corticosteroids, compared with rates of bone loss in 12 dual X-ray absorptiometry [1, 4, 5, [8] [9] [10] [11] 14] ; (ii) the different subjects (mean age 38.3 yr) treated with longmeasurements being confined to less sensitive cortical term corticosteroids. More advanced age and perimenosites [7] ; (iii) the effects of illness and steroid exposure pausal status may have contributed to the differing rates before commencement of the study which may underof bone loss. estimate the effect of corticosteroids [1-8, 10, 12, 16 ] ;
Studies of the pathogenesis of corticosteroid-related and (iv) selection bias; normal bone density in persons osteoporosis using histomorphometry, biochemical receiving < 10 mg daily may reflect bone loss from a measurements of bone turnover, in vitro models and high peak value (due to less severe illness and less animal models support the view that reduced bone immobilization) [1, 3, 5, 9, 14] .
formation is primarily responsible for corticosteroidIn most studies, participants have ongoing disease; related bone loss [18] [19] [20] [21] [22] [23] . Although disease itself may bone loss due to the disease or the corticosteroids suppress osteocalcin [23] , baseline osteocalcin was cannot be distinguished [2, 5, 7-10, 12, 29] . The data normal in this study and decreased in the first month in the present study support the findings of a randomof treatment. At the final measurement, osteocalcin ized control trial in which lumbar spine bone density was 26% lower in the patients than the controls; decreased in prednisone-treated rheumatoid arthritis however, the patients were receiving very low doses of patients and did not change in the placebo group [15] .
corticosteroids at this time and osteocalcin had been Although in the present study there is no means of recovering to normal levels after being suppressed by entirely distinguishing the effect of corticosteroids from the higher doses at the beginning of the study. An those of the disease, it is likely that the bone loss can increase in bone-specific alkaline phosphatase was be attributed to the corticosteroids, not the polymyalobserved in this and in several other studies. The gia rheumatica, for the following reasons: (i) bone loss significance of this observation is uncertain [28, [45] [46] [47] [48] . occurred despite improvement in muscle strength, a
The fall in androstenedione and DHEA-S may have reduction in pain, joint stiffness and in the ESR; contributed, in part, to the reduced bone formation (ii) serum osteocalcin was not suppressed before treat- [33, 49] . A decline in serum testosterone was not ment, decreased during the first month of therapy detected in this study, perhaps because the effects of when the doses of prednisolone were around 9 mg corticosteroids are dose related [50] . The significance daily, and then remained reduced throughout the treatof the increase in serum IGF-1 reported here and ment period; (iii) there was an association between the elsewhere is uncertain [51, 52] . fall in bone density and the cumulative dose of
The pathogenesis of corticosteroid-related bone loss corticosteroids.
is also commonly attributed to increased bone resorpThe data presented here suggest that bone loss tion, despite there being little evidence to support this differed from region to region. Bone loss occurred at view. We found no biochemical evidence of increased sites containing substantial amounts of trabecular bone resorption. The higher pre-treatment biochemical bone, such as the spine and trochanter, during the first measure of bone resorption (urinary CTX excretion) 6 months. Bone loss at the femoral neck was detectable and suppressed PTH are consistent with increased in the later months of follow-up. Several investigators bone resorption being due to the underlying disease have reported that bone loss is detected earlier at sites before treatment was started. The fall in the urinary containing trabecular bone, with cortical bone loss CTX may be due to disease remission. Resorption may emerging later so that, after long-term corticosteroids, 'increase' by increased depth and increased numbers deficits occur throughout the skeleton [8, 11, [40] [41] [42] .
of resorption sites. Neither have been demonstrated to The bone loss was~2-5% during the 14 months with result from exposure to corticosteroids. On the conno evidence of bone loss in controls. These rates of trary, in vitro, there is a dose-dependent reduction in loss are 2-4 times higher than those encountered in the number and area of excavations, a reduction healthy subjects of the same age and gender [43] . If in osteoclast numbers and survival rate [54, 55] . these rates of bone loss persist, then the risk of fracture Interstitial wall thickness is not reduced [19] . ( This will double within~2-3 yr [44] . distance between two cement lines of adjacent resorpLoCascio et al. [2] reported that most of the decrease tion should be reduced if the depth of a resorption in iliac crest trabecular bone volume occurred in the cavity is increased [19] .) Failure to fill resorption sites first 5-7 months of treatment with no reduction in the may be partly responsible for the increased extent of following 6 months. This conclusion was based on resorption surfaces in iliac crest bone biopsy samples three sequential bone biopsies in four of 19 subjects without prior exposure to treatment. Only trabecular from patients receiving corticosteroids [19] . 
